Rallybio logo
Rallybio
RLYB | NASDAQ
Chart Builder DCF Calculator
$15.43
-$0.29 (-1.84%)
At close: Nov 16, 2026, 4:00 PM ET
$15.38
-$0.05 (-0.33%)
After-hours: Nov 16, 2026, 7:33 PM ET

Rallybio Company Profile

Company profile explained

Company Profile

Rallybio Corporation is a clinical-stage biotechnology firm dedicated to discovering and bringing to market transformative therapies for individuals facing severe and uncommon illnesses. Its most advanced therapeutic candidate, RLYB212, is a monoclonal anti-HPA-1a antibody currently undergoing Phase II clinical trials. This candidate, along with RLYB211, is aimed at preventing fetal and neonatal alloimmune thrombocytopenia (FNAIT). The company's pipeline also includes RLYB114, a pegylated complement factor 5 (C5)-targeted Affibody molecule in preclinical development for addressing ophthalmic conditions driven by complement system activity. Furthermore, RLYB116, an inhibitor designed to target complement component 5 (C5) for various complement dysregulation disorders, has successfully completed its Phase 1 trial. Another preclinical antibody, RLYB332, is under investigation for treating severe anemia characterized by ineffective erythropoiesis and iron overload. Rallybio has established strategic collaborations to further its development efforts. It maintains an alliance with AbCellera for the identification, development, and commercialization of novel antibody-based therapeutics in rare diseases. Additionally, the firm partners with Exscientia on the creation of small molecule therapeutics for rare diseases, and with Johnson & Johnson to deliver therapeutic options to expectant mothers at risk of fetal and neonatal alloimmune thrombocytopenia. Established in 2018, Rallybio Corporation is headquartered in New Haven, Connecticut.

Key Executives

Name Position
Stephen Uden Co-Founder, President, Chief Executive Officer & Director
Jonathan I. Lieber Chief Financial Officer & Treasurer
Martin W. MacKay Co-Founder & Chairman

Latest SEC Filings

Date Type Title
Oct 30, 2026 4 Filing
Oct 29, 2026 4 Filing
Oct 28, 2026 4 Filing
Oct 28, 2026 4 Filing
Oct 27, 2026 10-Q Quarterly Report
Oct 26, 2026 425 Filing
Oct 26, 2026 8-K Current Report
Oct 20, 2026 4 Filing
Oct 20, 2026 4 Filing
Oct 15, 2026 EFFECT Filing
View All SEC Filings ➞
Rallybio
Rallybio logo
Country United States
IPO Date Jul 29, 2021
Industry Biotechnology
Sector Healthcare
Employees 14
CEO Stephen Uden

Contact Details

234 Church Street New Haven, Connecticut 06510 United States

Stock Details

Ticker Symbol RLYB
Exchange NASDAQ
Fiscal Year January - December
Reporting Currency USD
CIK Code 0001739410
CUSIP Number 75120L209
ISIN Number US75120L2097
SIC Code 2834

© 2026 bestshares.com. All rights reserved.

All data is for informational purposes only. bestshares.com is not a broker, dealer, or registered investment adviser, and nothing on this site is a recommendation to buy or sell any security.